• Skip to main content
  • Main Menu
  • Navigation for access to support pages
  • Navigation for access to legal pages
 Logo Viva Technology
  • Session Recordings
  • Speakers
  • Exhibitors
  • FAQ
  • confirmation_numberGet Your 2026 Pass
  • Become a Partner
 Viva Technology

17-20 June 2026

Paris Expo Porte de Versailles

1 Place de la Porte de Versailles

F-75015 Paris France

More Infoarrow_right_alt

Event organizers

2025 ThemesConference ProgramOur Speakers

Exhibitors at VivaTech2025 Partners

Startups at VivaTechInvestors at VivaTech2025 Startup Challenges and Awards

JournalistsMedia Partners2025 PresskitPress Releases

About UsOur CommitmentsPractical InformationBook Your Stay

©Viva Technology 2016-2025 all rights reserved

Site MapSite noticeB2B terms & conditionsData Privacy
Fanny Jaulin Co-Founder & CEO at Orakl Oncology
  1.  Logo Viva Technology
  2. Speakers
  3. Fanny Jaulin
 Photo Fanny Jaulin

Fanny Jaulin

Co-Founder & CEO

Orakl Oncology

#
Deep Tech & Quantum Computing
Healthcare & Wellness

About Me

From academia to entrepreneurship: the journey has been exciting, challenging and deeply rewarding. Leveraging years of research in cancer cell biology and precision oncology, I've transitioned from exploring theories to building real-world solutions to bring more drugs to cancer-patients. Driven by a future shaped by science and bold ideas, I am not only pushing scientific and technological boundaries but now aiming for societal impact in health.

Hear My Insights

The AI Frontier: A Founder's Vision for Cancer's Future

What if AI could drastically accelerate the development of cancer treatments? This is the challenge French startup Orakl Oncology is tackling head-on. In this session, discover how the company is reshaping drug development by combining real-world patient data with cutting-edge biology to create an AI-powered platform. Join the founder, in conversation with a key investor, as they reveal how this approach is redefining the future of oncology, improving clinical trial success, and driving the next generation of cancer therapies.